Genfit SA GNFT
EURONEXT · France · Health Technology
€9.44-0.48 (-4.84%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Financial Highlights Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028€21.1 million in revenues as of June 30, 2026, including €21.0 million in royalties generated under the Ipsen agreement Key Highlights PBC: Ipsen doubled its peak annual global sales target for Iqirvo® in PBC to €1 billion, underscoring the value creation potential of GENFIT's licensing agreementMASH: Medicare coverage secured in August 2026 in the United
GENFIT's acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needsThe investigation in Phase 2 is supported by a robust scientific and clinical foundation around the TREM-1 pathway and the asset's profile: Strong knowledge of nangibotide’s biological pathwayMultiple efficacy signals already observed with nangibotide across three Phase 2 clinical trials in septic shock and COVID-19 subjects, includ
Lille (France), Cambridge (Massachusetts, United States), September 11, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit GENFIT to the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, September 18, 2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.